Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05665699 · ClinicalTrials.gov registry record · Phase 2

Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout

A Phase 2 study of Gout, sponsored by InventisBio Co..

Active
Registry status
Phase 2
Development phase
80
Enrollment target
19
Study locations

NCT05665699: Active Phase 2 study of Gout, sponsored by InventisBio Co..

NCT05665699 is a Phase 2 study of Gout that is active but no longer recruiting, run by InventisBio Co.. The registered enrollment target is 80 participants, below the 8,886-participant average among 34 other Gout trials with a reported enrollment target (99% lower). The trial reports 19 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05665699, a Phase 2 study of Gout, is active but no longer recruiting, sponsored by InventisBio Co..

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
80 participants
Enrollment target
19
Study locations

Study Summary

D-0120 is being tested in combination with Allopurinol in adult subjects with Gout.

Conditions Studied

Gout

Interventions

  • DRUG Allopurinol
  • DRUG D-0120

Study Locations (19)

North Carolina

  • Study Center - Hickory
  • Study Center - Rocky Mount
  • Study Center - Salisbury
  • Study Center - Wilmington
  • Study Center - Winston-Salem

Tennessee

  • Study Center - Bristol
  • Site Center - Hendersonville
  • Study Center - Knoxville

Texas

  • Site Center - Fort Worth
  • Site Center - The Woodlands

Alabama

  • Study Center - Birmingham

Florida

  • Site Center - Plantation

Illinois

  • Study Center - Evergreen Park

Indiana

  • Study Center - Brownsburg

Kentucky

  • Site Center - Louisville

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2023-04-17
Est. Completion 2025-12-30
Phase Phase 2
InventisBio Co.

11 total trials

What the registry record for NCT05665699 still lists

NCT05665699 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 8,886-participant average among 34 other Gout trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Gout appearing as the primary indexed condition, and to 2 interventions - of which Allopurinol is the first listed.

NCT05665699 lists 19 locations in 12 states (North Carolina, Tennessee, Texas).

Frequently Asked Questions

What is clinical trial NCT05665699 about?

NCT05665699 is a clinical study titled "Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout". D-0120 is being tested in combination with Allopurinol in adult subjects with Gout.

What is the current status of trial NCT05665699?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2023-04-17. Estimated completion is 2025-12-30.

What conditions does trial NCT05665699 study?

This clinical trial studies the following conditions: Gout.

What interventions are being tested in trial NCT05665699?

The interventions under investigation include: Allopurinol (DRUG), D-0120 (DRUG).

Who is sponsoring clinical trial NCT05665699?

This trial is sponsored by InventisBio Co., which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05665699 being conducted?

This trial has 19 study locations across Alabama, Florida, Illinois, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gout

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05665699's enrollment target sits among peer trials

80 19th of 34 higher than 16 of 34 other Gout trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Gout trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05665699, the US trial registry maintained by the National Library of Medicine. NCT05665699 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.